The study focused on the gene regulator grainyhead-like 2 (GRHL2), which the research group has been investigating for a several years. As Dr. Walentin and Professor Schmidt-Ott have now shown, this regulator plays a key role in the development of the placenta. In a previous study, Professor Schmidt-Ott and his team discovered that it regulates the differentiation of epithelial cells – they line the cavities and surfaces of structures throughout the body – in the mouse embryo.
In the current study, the researchers noted that GRHL2 is very active in the healthy placenta, especially in trophoblast cells, which are responsible for the development of the labyrinth. This placental labyrinth forms the interface between the blood circulation of the embryo and the mother. It ensures the exchange of nutrients and oxygen as well as the removal of embryonic metabolic end products. The trophoblast cells branch out to form the labyrinth, and they are accompanied by fetal blood vessels. Thereby, a large interface is created to facilitate the exchange of metabolites between mother and fetus.
In mice, when the researchers inactivated the gene regulator GRHL2 in the fetal part of the placenta and in the embryo, the development of the labyrinth was severely disrupted. In particular, the branching of the trophoblast cells and the migration of the fetal blood vessels into the placenta were impaired. When the researchers inactivated the gene regulator only outside the placenta in the embryo, the labyrinth developed normally. Using genome-wide analyses, the MDC researchers found that GRHL2 regulates a defined gene program. Components of this program are critically involved in the development of the placenta.
During their studies, which were funded by the German Research Foundation (DFG ) and the Urological Research Foundation, the researchers additionally discovered that GRHL2 and its target genes also display activity in the human placenta. They hope that these findings could be significant for the understanding of developmental abnormalities of the placenta and related pregnancy disorders in humans.
*A Grhl2-dependent gene network controls trophoblast branching morphogenesis
Katharina Walentin,1,2 Christian Hinze,1,2 Max Werth,1,2,3 Nadine Haase,2 Saaket Varma,4 Robert Morell,5 Annekatrin Aue,1,2 Elisabeth Pötschke,1 David Warburton,4 Andong Qiu,3 Jonathan Barasch,3 Bettina Purfürst,1 Christoph Dieterich,6 Elena Popova1, Michael Bader1, Ralf Dechend,2 Anne Cathrine Staff,7 Zeliha Yesim Yurtdas,1,8,9 Ergin Kilic,10 and Kai M. Schmidt-Ott1,2,11,*
1Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin, Germany.2Experimental and Clinical Research Center, a collaboration between the Max Delbrück Center and the Medical Faculty of the Charité, Robert-Rössle-Str. 10, 13125 Berlin, Germany. 3Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. 4Department of Developmental Biology and Regenerative Medicine Program, Saban Research Institute, Children's Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA. 5Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders (NIDCD)/National Institutes of Health (NIH), 5Research Court, Rockville, MD 20850, USA.6Bioinformatics, Max Planck Institute for Biology of Ageing, Robert-Koch-Str. 21, 50931 Cologne, Germany. 7Department of Gynecology and Obstetrics, Institute of Clinical Medicine, Oslo University Hospital and University of Oslo, Kirkeveien 166, 0450 Oslo, Norway. 8Department of Urology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 9Berlin Institute of Urologic Research, Berlin, Germany. 10Department of Pathology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 11Department of Nephrology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
in the Helmholtz Association
Phone: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30 94 06 - 38 33